A Randomized Phase 2 Study to Evaluate Safety and Efficacy of the Combination of SHR-1210 With Capecitabine + Oxaliplatin or Apatinib as First-line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 25 May 2018
At a glance
- Drugs Camrelizumab (Primary) ; Capecitabine; Oxaliplatin; Rivoceranib
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 15 May 2018 Status changed from not yet recruiting to recruiting.
- 22 Mar 2018 New trial record